Zydus receives final approval from the USFDA for Ketorolac Tromethamine Tablets

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Ketorolac Tromethamine Tablets USP, 10 mg (USRLD: Toradol®).

Ketorolac Tromethamine Tablets are indicated to relieve moderately severe pain, usually after surgery. The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.

Ketorolac Tromethamine Tablets had annual sales of USD 17mn in the United States according to IQVIA data (IQVIA MAT Aug 2022).

The group now has 328 approvals and has so far filed over 428* ANDAs since the commencement of the filing process in FY 2003-04.

(*as of 30th June 2022)

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 409.95 as compared to the previous close of Rs. 413.95. The total number of shares traded during the day was 17537 in over 868 trades.

The stock hit an intraday high of Rs. 416.00 and intraday low of 408.85. The net turnover during the day was Rs. 7208895.00.

Source : Equity Bulls

Keywords

Zydus Lifesciences INE010B01027 USFDA FinalApproval KetorolacTromethamineTablets